SimianX AI LogoSimianX AI

Asset profile

XmAb819 · Xencor (XNCR)

Indication
advanced clear cell renal cell carcinoma (ccRCC)
Also known as
ENPP3 x CD3, ENPP3 x CD3 bispecific, XmAb 2+1 bispecific antibody, ENPP3 x CD3 bispecific antibody
CompanyXNCRXencor

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product cand…

Start live analysis of XNCRRun 8-agent AI analysis

On the calendar

25
Oct 2026
Oct 25, 2026
6 days ago
XNCRXencor

Xencor XmAb819 Phase 1 ESMO 2026 oral presentation and webcast

Rescheduled — was Oct 1, 2026

Conference presentationOutcome not recordedSEC 8-K

Timeline

Newest first.

Oct 26, 2026
11:50 AM
XNCRXencor

Xencor XmAb819 Phase 1 dose-expansion data in advanced ccRCC

Topline resultsSEC 8-KOpen record
Oct 25, 2026
08:35 AM
XNCRXencor

Xencor Presents XmAb819 Phase 1 Data at ESMO 2026, Selects RP3D and Plans FDA Discussion in 1H2027

Conference presentationCompany press release
Oct 19, 2026
11:01 AM
XNCRXencor

Xencor XmAb819 Phase 1 ESMO 2026 oral presentation and webcast

Trial registry changeCompany press release
Aug 5, 2026
08:01 PM
XNCRXencor

Xencor: XmAb819 ccRCC data accepted for ESMO 2026 oral presentation

Conference presentationSEC 8-K

More from Xencor

Other drugs and candidates from the same company tracked in this sector.

tafasitamabfirst-line diffuse large B-cell lymphoma (DLBCL)
XmAb819 · Xencor (XNCR) — FDA Timeline & Readiness Checklist | SimianX AI